In another study, bevacizumab combined with EGFR tyrosine kinase inhibitor reduced circulating S100A9 positive MDSCs and improved progression-free survival in patients with EGFR mutant lung adenocarcinoma (Feng et al., 2018). The gene discussed is EGFR; the disease is lung adenocarcinoma.